[1]徐冲,陈蕊,周烨,等.T 细胞在肺动脉高压发病中的作用[J].国际心血管病杂志,2023,06:341-345.
点击复制
T 细胞在肺动脉高压发病中的作用(PDF)
《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]
- 期数:
- 2023年06期
- 页码:
- 341-345
- 栏目:
- 综述
- 出版日期:
- 2023-11-20
文章信息/Info
- Title:
- -
- Author(s):
- -
- Keywords:
- -
- 分类号:
- -
- DOI:
- 10.3969/j.issn.1673-6583.2023.06.002
- 文献标识码:
- -
- 摘要:
- 肺动脉高压（PAH）是多种病因引起的慢性进行性疾病，免疫炎症因素在肺血 管重构过程中起重要作用。T 细胞作为一把双刃剑，通过与肺血管细胞、右心室细胞及其他 免疫细胞的相互作用，在PAH 中发挥促进或抑制免疫炎症作用，T 细胞有望成为防治PAH 的靶点。
- Abstract:
- -
参考文献/References
[1] Li L, Jick S, Breitenstein S, et al. Pulmonary arterial
hypertension in the USA: an epidemiological study in a large
insured pediatric population[J]. Pulm Circ, 2017, 7(1):126-
136.
[2] Chen S, Yan D, Qiu A. The role of macrophages in
pulmonary hypertension: pathogenesis and targeting[J]. Int
Immunopharmacol, 2020, 88:106934.
[3] Wang RR, Yuan TY, Wang JM, et al. Immunity and
inflammation in pulmonary arterial hypertension: from
pathophysiology mechanisms to treatment perspective[J].
Pharmacol Res, 2022, 180:106238.
[4] Brandstadter JD, Maillard I. Notch signalling in T cell
homeostasis and differentiation[J]. Open Biol, 2019,
9(11):190187.
[5] Hu YJ, Chi L, Kuebler WM, et al. Perivascular inflammation
in pulmonary arterial hypertension[J]. Cells, 2020, 9(11):2338.
[6] Maston LD, Jones DT, Giermakowska W, et al. Central role
of T helper 17 cells in chronic hypoxia-induced pulmonary
hypertension[J]. Am J Physiol Lung Cell Mol Physiol, 2017,
312(5):L609-L624.
[7] van Uden D, Koudstaal T, van Hulst JAC, et al. Peripheral
blood T cells of patients with IPAH have a reduced cytokineproducing
capacity[J]. Int J Mol Sci, 2022, 23(12):6508.
[8] Chen GL, Zuo SK, Tang J, et al. Inhibition of CRTH2-
mediated Th2 activation attenuates pulmonary hypertension in
mice[J]. J Exp Med, 2018, 215(8):2175-2195.
[9] Austin ED, Rock MT, Mosse CA, et al. T lymphocyte subset
abnormalities in the blood and lung in pulmonary arterial
hypertension[J]. Respir Med, 2010, 104(3):454-462.
[10] Edwards AL, Gunningham SP, Clare GC, et al. Professional
killer cell deficiencies and decreased survival in pulmonary
arterial hypertension[J]. Respirology, 2013, 18(8):1271-1277.
[11] Qiu HH, He Y, Ouyang F, et al. The role of regulatory T cells
in pulmonary arterial hypertension[J]. J Am Heart Assoc,
2019, 8(23):e014201.
[12] Meng X, Yang JM, Dong M, et al. Regulatory T cells in
cardiovascular diseases[J]. Nat Rev Cardiol, 2016, 13(3):167-
179.
[13] Tamosiuniene R, Manouvakhova O, Mesange P, et al.
Dominant role for regulatory T cells in protecting females
against pulmonary hypertension[J]. Circ Res, 2018,
122(12):1689-1702.
[14] Balabanian K, Foussat A, Dorfmüller P, et al. CX(3)C
chemokine fractalkine in pulmonary arterial hypertension[J].
Am J Respir Crit Care Med, 2002, 165(10):1419-1425.
[15] Liu HL, Pan ZH, Ma XD, et al. ROCK inhibitor fasudil
reduces the expression of inflammatory factors in LPS-induced
rat pulmonary microvascular endothelial cells via ROS/NF-κB
pathway[J]. BMC Pharmacol Toxicol, 2022, 23(1):24.
[16] Ye JX, Wang SS, Ge M, et al. Suppression of endothelial
PGC-1α is associated with hypoxia-induced endothelial
dysfunction and provides a new therapeutic target in
pulmonary arterial hypertension[J]. Am J Physiol Lung Cell
Mol Physiol, 2016, 310(11):L1233-L1242.
[17] Florentin J, Zhao JS, Tai YY, et al. Interleukin-6 mediates
neutrophil mobilization from bone marrow in pulmonary
hypertension[J]. Cell Mol Immunol, 2021, 18(2):374-384.
[18] Smolders VFED, Rodríguez C, Blanco I, et al. Metabolic
profile in endothelial cells of chronic thromboembolic
pulmonary hypertension and pulmonary arterial hypertension[J]. Sci Rep, 2022, 12(1):2283.
[19] Certo M, Elkafrawy H, Pucino V, et al. Endothelial cell
and T-cell crosstalk: targeting metabolism as a therapeutic
approach in chronic inflammation[J]. Br J Pharmacol, 2021,
178(10):2041-2059.
[20] Marrodan M, Farez MF, Balbuena Aguirre ME, et al. Obesity
and the risk of multiple sclerosis. The role of leptin[J]. Ann
Clin Transl Neurol, 2021, 8(2):406-424.
[21] Gorelova A, Berman M, Al Ghouleh I. Endothelial-tomesenchymal
transition in pulmonary arterial hypertension[J].
Antioxid Redox Signal, 2021, 34(12):891-914.
[22] Mitani Y, Ueda M, Komatsu R, et al. Vascular smooth muscle
cell phenotypes in primary pulmonary hypertension[J]. Eur
Respir J, 2001, 17(2):316-320.
[23] Chu YB, Xiangli XY, Xiao W. Regulatory T cells protect
against hypoxia-induced pulmonary arterial hypertension in
mice[J]. Mol Med Rep, 2015, 11(4):3181-3187.
[24] Li C, Liu PP, Tang DD, et al. Targeting the RhoA-ROCK
pathway to regulate T-cell homeostasis in hypoxia-induced
pulmonary arterial hypertension[J]. Pulm Pharmacol Ther,
2018, 50:111-122.
[25] Qian J, Tian W, Jiang X, et al. Leukotriene B4 activates
pulmonary artery adventitial fibroblasts in pulmonary
hypertension[J]. Hypertension, 2015, 66(6):1227-1239.
[26] Bansal SS, Ismahil MA, Goel M, et al. Dysfunctional and
proinflammatory regulatory T-lymphocytes are essential for
adverse cardiac remodeling in ischemic cardiomyopathy[J].
Circulation, 2019, 139(2):206-221.
[27] Kumar R, Mickael C, Kassa B, et al. Interstitial macrophagederived
thrombospondin-1 contributes to hypoxia-induced
pulmonary hypertension[J]. Cardiovasc Res, 2020,
116(12):2021-2030.
[28] van Uden D, Boomars K, Kool M. Dendritic cell subsets and
effector function in idiopathic and connective tissue diseaseassociated
pulmonary arterial hypertension[J]. Front Immunol,
2019, 10:11.
[29] Hautefort A, Girerd B, Montani D, et al. T-helper 17 cell
polarization in pulmonary arterial hypertension[J]. Chest,
2015, 147(6):1610-1620.
[30] Sasaki CY, Chen G, Munk R, et al. p(70S6K1) in the TORC1
pathway is essential for the differentiation of Th17 cells, but
not Th1, Th2, or Treg cells in mice[J]. Eur J Immunol, 2016,
46(1):212-222.
[31] McMurtry MS, Bonnet S, Michelakis ED, et al. Statin therapy,
alone or with rapamycin, does not reverse monocrotaline
pulmonary arterial hypertension: the rapamcyin-atorvastatinsimvastatin
study[J]. Am J Physiol Lung Cell Mol Physiol,
2007, 293(4):L933-L940.
[32] Wessler JD, Steingart RM, Schwartz GK, et al. Dramatic
improvement in pulmonary hypertension with rapamycin[J].
Chest, 2010, 138(4):991-993.
[33] Kadavath S, Zapantis E, Zolty R, et al. A novel therapeutic
approach in pulmonary arterial hypertension as a complication
of adult-onset Still's disease: targeting IL-6[J]. Int J Rheum
Dis, 2014, 17(3):336-340.
[34] Toshner M, Church C, Harbaum L, et al. Mendelian
randomisation and experimental medicine approaches
to interleukin-6 as a drug target in pulmonary arterial
hypertension[J]. Eur Respir J, 2022, 59(3):2002463.
[35] Zamanian RT, Badesch D, Chung L, et al. Safety and efficacy
of B-cell depletion with rituximab for the treatment of
systemic sclerosis-associated pulmonary arterial hypertension:
a multicenter, double-blind, randomized, placebo-controlled
trial[J]. Am J Respir Crit Care Med, 2021, 204(2):209-221.
[36] Koudstaal T, Boomars KA, Kool M. Pulmonary arterial
hypertension and chronic thromboembolic pulmonary
hypertension: an immunological perspective[J]. J Clin Med,
2020, 9(2):561.
[37] Liu Y, Shi JZ, Jiang R, et al. Regulatory T cell-related gene
indicators in pulmonary hypertension[J]. Front Pharmacol,
2022, 13:908783.
[38] Bluestone JA, Buckner JH, Fitch M, et al. Type 1 diabetes
immunotherapy using polyclonal regulatory T cells[J]. Sci
Transl Med, 2015, 7(315):315ra189.
[39] Liu MY, Zhen X, Song HY, et al. Low-dose lymphocyte
immunotherapy rebalances the peripheral blood Th1/Th2/
Treg paradigm in patients with unexplained recurrent
miscarriage[J]. Reprod Biol Endocrinol, 2017, 15(1):95.
[40] Elahi R, Khosh E, Tahmasebi S, et al. Immune cell hacking:
challenges and clinical approaches to create smarter
generations of chimeric antigen receptor T cells[J]. Front
Immunol, 2018, 9:1717.
备注/Memo
- 备注/Memo:
-
基金项目：江苏省自然科学基金面上项目（BK20181227）；江苏
省青年医学人才项目（QNRC2016835）；江苏省“六大人才高
峰”高层次人才选拔培养项目（WSN126）；金山英才医学领域高
层次人才引进项目（JSYCBS202103）；江苏省重点研发计划项目
（BE2021694）
通信作者：陈蕊， E-mail：chenruicardiology@aliyun.com
常用功能
统计/Statistics
- 摘要浏览/Viewed7
- 全文下载/Downloads252
- 评论/Comments
